Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
15.01
+0.21 (1.39%)
Jan 22, 2025, 10:58 AM EST - Market open
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 27,048 employees as of March 31, 2024. The number of employees increased by 1,185 or 4.58% compared to the previous year.
Employees
27,048
Change (1Y)
1,185
Growth (1Y)
4.58%
Revenue / Employee
$132,324
Profits / Employee
$23,534
Market Cap
12.49B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 27,048 | 1,185 | 4.58% |
Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
Mar 31, 2020 | 21,650 | -316 | -1.44% |
Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
Mar 31, 2018 | 23,524 | 853 | 3.76% |
Mar 31, 2017 | 22,671 | 496 | 2.24% |
Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
Mar 31, 2012 | 15,200 | 277 | 1.86% |
Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
Mar 31, 2008 | 9,575 | 555 | 6.15% |
Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
Mar 31, 2005 | 6,135 | -20 | -0.32% |
Mar 31, 2004 | 6,155 | 303 | 5.18% |
Mar 31, 2003 | 5,852 | 409 | 7.51% |
Mar 31, 2002 | 5,443 | 314 | 6.12% |
Mar 31, 2001 | 5,129 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
RDY News
- 7 weeks ago - Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma - Business Wire
- 2 months ago - Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market - Business Wire
- 2 months ago - Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Dr. Reddy's Q2 & H1FY25 Financial Results - Business Wire
- 3 months ago - Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year - Business Wire
- 3 months ago - Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month - Business Wire
- 3 months ago - Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma - Business Wire
- 4 months ago - Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries - Business Wire